23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › HALOZYME THERAPEUTICS INC. › 2023-2024

HALOZYME THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and HALOZYME THERAPEUTICS INC.’s Form 8-K, filed April 26, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 434Asset managers, any item
  • 3,009Fund votes
  • April 25, 2024Meeting date

Results at a glance

Meeting of April 25, 2024: 5 items on HALOZYME THERAPEUTICS INC.’s Form 8-K, filed April 26, 2024: 3 approved · 2 passed (calculated).

Dissent

Notable dissent: 1 director (14.3% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore HALOZYME THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by HALOZYME THERAPEUTICS INC.

These tallies are HALOZYME THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed April 26, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

HALOZYME THERAPEUTICS INC. — official shareholder meeting results, meeting held April 25, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Barbara Duncan 90,120,42415,016,536161,704 --10,383,116 86%Passed (calculated)—
Elect Director: Mahesh Krishnan, M.D. 103,968,6631,164,017165,984 --10,383,116 99%Passed (calculated)—
2. Advisory vote on the compensation of the Company's named executive officers 102,860,4352,190,603247,626 --10,383,116 98%Approved—
3. Proposal to approve an amendment to the Company's Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding exculpation of officers 91,512,25213,612,616173,796 --10,383,116 87%Approved—
4. Proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 114,912,469647,868121,443 ---- 99.4%Approved—

This meeting is also recorded here as April 26, 2024; both records come from the same filing, so the date should be checked against it.

Source: HALOZYME THERAPEUTICS INC., Form 8-K, filed with the SEC on April 26, 2024 — read the filing on EDGAR.

How asset managers voted at the HALOZYME THERAPEUTICS INC. 2023-2024 meeting

434 asset managers disclosed a vote on at least one HALOZYME THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Barbara Duncan

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%AGAINST
FOR: 90,120,424AGAINST: 15,016,536
Details: description as filed, official tally, votes by 123 asset managers

Description as filed by funds: Election of Class II Directors: Barbara Duncan

HALOZYME THERAPEUTICS INC.’s own tally for this item (“Elect Director: Barbara Duncan”): 90,120,424 for, 15,016,536 against, per its Form 8-K filed April 26, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 86% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 123 asset managers below reported 52,576,135 for, 7,776,543 against, 62,687 abstained.

FOR
FOR: 52,576,135AGAINST: 7,776,543ABSTAIN: 62,687
Largest asset managers voting on “Election of Class II Directors: Barbara Duncan” at HALOZYME THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard14,892,8350 00For
BlackRock10,711,1380 00For
Fidelity3,209,06844,852 00For
State Street58,3722,768,522 00Against
Delaware/Macquarie02,076,163 00Against
Artisan2,028,4250 00For
Charles Schwab1,720,0610 00For
Thrivent1,695,4430 00For
JPMorgan1,623,7450 00For
TIAA1,460,4810 00For
First Trust1,201,5330 00For
AllianceBernstein1,059,0540 00For
Invesco01,004,224 00Against
T. Rowe Price970,5960 00For
Dimensional815,8460 00For
Jackson National455,295340,856 00Mixed
Equitable720,9240 00For
American Century682,1920 00For
Brighthouse144,234413,107 00Mixed
AB DISCOVERY GROWTH FUND, INC.500,3920 00For
BUFFALO FUNDS482,6340 00For
Federated Hermes468,8040 00For
AIG/SunAmerica461,9350 00For
Columbia Threadneedle380,3600 00For
MERIDIAN FUND INC372,8200 00For

Showing the 25 largest of 123 asset managers. All 123 are in the interactive database (link above).

Elect Director: Mahesh Krishnan, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 103,968,663AGAINST: 1,164,017
Details: description as filed, official tally, votes by 123 asset managers

Description as filed by funds: Election of Class II Directors: Mahesh Krishnan

HALOZYME THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mahesh Krishnan, M.D.”): 103,968,663 for, 1,164,017 against, per its Form 8-K filed April 26, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 123 asset managers below reported 60,091,787 for, 260,891 against, 62,687 abstained.

FOR
FOR: 60,091,787AGAINST: 260,891ABSTAIN: 62,687
Largest asset managers voting on “Election of Class II Directors: Mahesh Krishnan” at HALOZYME THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard14,892,8350 00For
BlackRock10,711,1380 00For
Fidelity3,209,06844,852 00For
State Street2,826,8940 00For
Delaware/Macquarie2,076,1630 00For
Artisan2,028,4250 00For
Charles Schwab1,720,0610 00For
Thrivent1,695,4430 00For
JPMorgan1,623,7450 00For
TIAA1,460,4810 00For
First Trust1,201,5330 00For
AllianceBernstein1,059,0540 00For
Invesco1,004,2240 00For
T. Rowe Price970,5960 00For
Dimensional815,8460 00For
Jackson National796,1510 00For
Equitable720,9240 00For
American Century682,1920 00For
Brighthouse557,3410 00For
AB DISCOVERY GROWTH FUND, INC.500,3920 00For
BUFFALO FUNDS482,6340 00For
Federated Hermes468,8040 00For
AIG/SunAmerica461,9350 00For
Columbia Threadneedle380,3600 00For
MERIDIAN FUND INC372,8200 00For

Showing the 25 largest of 123 asset managers. All 123 are in the interactive database (link above).

Proposal to approve an amendment to the Company's Amended and Restated Certificate of Incorporation to reflect Delaware…

Official resultCORPORATE GOVERNANCEReported outcome: Approved

Combines 6 wordings of this item as funds reported it.

87% Approved · of votes cast

FOR 87%
FOR: 91,512,252AGAINST: 13,612,616
Details: description as filed, official tally, votes by 123 asset managers

Description as filed by funds: To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding exculpation of officers.

HALOZYME THERAPEUTICS INC.’s own tally for this item (“3. A proposal to approve an amendment to the Company's Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding exculpation of officers”): 91,512,252 for, 13,612,616 against — passed, per its Form 8-K filed April 26, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The foregoing proposal was approved.”
Support: 87% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 123 asset managers below reported 55,677,455 for, 4,675,989 against, 61,921 abstained.

FOR
FOR: 55,677,455AGAINST: 4,675,989ABSTAIN: 61,921
Largest asset managers voting on “To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to reflect Delaware” at HALOZYME THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard13,782,6991,110,136 00Mixed
BlackRock10,711,1380 00For
Fidelity2,961,922291,998 00Mixed
State Street2,826,749145 00For
Delaware/Macquarie2,076,1630 00For
Artisan2,028,4250 00For
Charles Schwab1,720,0610 00For
Thrivent1,695,4430 00For
JPMorgan01,623,745 00Against
TIAA1,460,4810 00For
First Trust1,201,5330 00For
AllianceBernstein1,059,0540 00For
Invesco1,004,2240 00For
T. Rowe Price970,5960 00For
Dimensional815,8460 00For
Jackson National628,733167,418 00Mixed
Equitable720,9240 00For
American Century682,1920 00For
Brighthouse557,3410 00For
AB DISCOVERY GROWTH FUND, INC.500,3920 00For
BUFFALO FUNDS482,6340 00For
Federated Hermes468,8040 00For
AIG/SunAmerica461,9350 00For
Columbia Threadneedle380,3600 00For
MERIDIAN FUND INC0372,820 00Against

Showing the 25 largest of 123 asset managers. All 123 are in the interactive database (link above).

Advisory vote on the compensation of the Company's named executive officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 18 wordings of this item as funds reported it.

98% Approved · of votes cast

FOR 98%
FOR: 102,860,435AGAINST: 2,190,603
Details: description as filed, official tally, votes by 429 asset managers

Description as filed by funds: To approve, by a non-binding advisory vote, the compensation of the Company's named executive officers.

HALOZYME THERAPEUTICS INC.’s own tally for this item (“2. The advisory vote on the compensation of the Company's named executive officers”): 102,860,435 for, 2,190,603 against — passed, per its Form 8-K filed April 26, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The foregoing proposal was approved.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 123 asset managers voting on “To approve, by a non-binding advisory vote, the compensation of the Company's named executive officers.” at HALOZYME THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard14,892,8350 00For
BlackRock10,711,1380 00For
Artisan5,263,6840 00For
Fidelity3,253,9200 00For
State Street2,826,8940 00For
Delaware/Macquarie2,076,1630 00For
Charles Schwab1,720,0610 00For
Thrivent1,695,4430 00For
JPMorgan1,623,7450 00For
TIAA1,460,4810 00For
First Trust1,201,5330 00For
AllianceBernstein1,059,0540 00For
Invesco1,004,2240 00For
T. Rowe Price970,5960 00For
Dimensional815,8460 00For
Jackson National796,1510 00For
Equitable720,9240 00For
American Century682,1920 00For
Brighthouse557,3410 00For
AB DISCOVERY GROWTH FUND, INC.500,3920 00For
BUFFALO FUNDS482,6340 00For
Federated Hermes468,8040 00For
AIG/SunAmerica461,9350 00For
Columbia Threadneedle380,3600 00For
MERIDIAN FUND INC372,8200 00For

Fund voting reports, all 123 managers: 63,368,956 for, 191,746 against, 61,921 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 342 asset managers voting on “To approve, by a non-binding advisory vote, the compensation of the Company's named executive officers.” at HALOZYME THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
State Street6,135,7810 00For
New York Life5,000,0000 00For
BlackRock4,679,194997 00For
SNYDER CAPITAL MANAGEMENT L P3,592,4720 00For
AllianceBernstein3,399,8310 00For
GEODE CAPITAL MANAGEMENT, LLC2,941,5220 00For
JPMorgan2,767,1050 00For
GW&K Investment Management, LLC1,890,8590 00For
ArrowMark Colorado Holdings LLC1,849,6420 00For
Charles Schwab1,759,6860 00For
Thrivent1,725,1910 00For
Nuveen1,611,3090 00For
MELLON INVESTMENTS Corp1,378,1870 00For
T. Rowe Price1,226,9780 00For
Invesco1,184,3190 00For
Stephens Investment Management Group LLC1,166,2810 00For
Epoch Investment Partners, Inc.1,146,0480 00For
Man Group plc1,087,8900 00For
NEW YORK STATE COMMON RETIREMENT FUND917,7820 00For
Granite Investment Partners, LLC734,2050 00For
American Century703,2780 00For
Lazard691,1430 00For
Allspring638,2230 00For
PRINCIPAL GLOBAL INVESTORS557,2950 00For
Northern Trust527,60090 00For

Institutional-manager reports, all 342 managers: 63,254,636 for, 1,426,977 against, 32,850 abstained, 908 not voted, 979 unknown. Showing the 25 largest; every one is in the interactive database (link above).

Proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 6 wordings of this item as funds reported it.

99.4% Approved · of votes cast

FOR 99.4%
FOR: 114,912,469AGAINST: 647,868
Details: description as filed, official tally, votes by 123 asset managers

Description as filed by funds: To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.

HALOZYME THERAPEUTICS INC.’s own tally for this item (“4. A proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”): 114,912,469 for, 647,868 against — passed, per its Form 8-K filed April 26, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The foregoing proposal was approved.”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of HALOZYME THERAPEUTICS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Ratify Appointment of Independent Auditors” (2 managers, 46,783 for).

The 123 asset managers below reported 60,309,472 for, 43,972 against, 61,921 abstained.

FOR
FOR: 60,309,472AGAINST: 43,972ABSTAIN: 61,921
Largest asset managers voting on “To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm fo” at HALOZYME THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard14,892,8350 00For
BlackRock10,711,1380 00For
Fidelity3,253,9200 00For
State Street2,826,749145 00For
Delaware/Macquarie2,076,1630 00For
Artisan2,028,4250 00For
Charles Schwab1,720,0610 00For
Thrivent1,695,4430 00For
JPMorgan1,623,7450 00For
TIAA1,460,4810 00For
First Trust1,201,5330 00For
AllianceBernstein1,059,0540 00For
Invesco1,004,2240 00For
T. Rowe Price970,5960 00For
Dimensional815,8460 00For
Jackson National796,1510 00For
Equitable720,9240 00For
American Century682,1920 00For
Brighthouse557,3410 00For
AB DISCOVERY GROWTH FUND, INC.500,3920 00For
BUFFALO FUNDS482,6340 00For
Federated Hermes468,8040 00For
AIG/SunAmerica461,9350 00For
Columbia Threadneedle380,3600 00For
MERIDIAN FUND INC372,8200 00For

Showing the 25 largest of 123 asset managers. All 123 are in the interactive database (link above).

Not shown here: this season’s fund filings also report 1 item from the meeting of May 1, 2025, which belongs to the 2024-2025 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.

Largest HALOZYME THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 127,186,000 shares outstanding at the time of that meeting.

Fund voting reports: top HALOZYME THERAPEUTICS INC. shareholders by shares voted on “To approve, by a non-binding advisory vote, the compensation of the Company's named executive…”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 11.71%
2BlackRock 8.42%
3Artisan 4.14%
4Fidelity 2.56%
5State Street 2.22%
6Delaware/Macquarie 1.63%
7Charles Schwab 1.35%
8Thrivent 1.33%
9JPMorgan 1.28%
10TIAA 1.15%
Institutional-manager reports: top HALOZYME THERAPEUTICS INC. shareholders by shares voted on “To approve, by a non-binding advisory vote, the compensation of the Company's named executive…”, 2023-2024
#Asset manager % of shares outstanding
1State Street 4.82%
2New York Life 3.93%
3BlackRock 3.68%
4SNYDER CAPITAL MANAGEMENT L P 2.82%
5AllianceBernstein 2.67%
6GEODE CAPITAL MANAGEMENT, LLC 2.31%
7JPMorgan 2.18%
8GW&K Investment Management, LLC 1.49%
9ArrowMark Colorado Holdings LLC 1.45%
10Charles Schwab 1.38%

Reported HALOZYME THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

HALOZYME THERAPEUTICS INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock12,860,199 10.11%Form 13F, quarter ended March 31, 2024
Vanguard Group11,629,786 9.14%Form 13F, quarter ended March 31, 2024
Artisan Partners Limited Partnership6,689,058 5.26%Proxy statement (DEF 14A), table as of February 26, 2024
State Street6,487,303 5.10%Form 13F, quarter ended March 31, 2024
Geode Capital3,027,384 2.38%Form 13F, quarter ended March 31, 2024
Helen I. Torley2,400,040 1.89%Proxy statement (DEF 14A), table as of February 26, 2024
Invesco2,088,410 1.64%Form 13F, quarter ended March 31, 2024
Northern Trust1,791,904 1.41%Form 13F, quarter ended March 31, 2024
Morgan Stanley1,737,600 1.37%Form 13F, quarter ended March 31, 2024
Dimensional Fund Advisors1,688,229 1.33%Form 13F, quarter ended March 31, 2024

Percentages above are of 127,186,000 shares outstanding, as reported by HALOZYME THERAPEUTICS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At HALOZYME THERAPEUTICS INC.'s shareholder meeting held April 25, 2024, in the 2023-2024 proxy season, 434 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 3,009 separate fund positions. On the most widely held item on that ballot — To approve, by a non-binding advisory vote, the compensation of the Company's named executive… — HALOZYME THERAPEUTICS INC.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: HALOZYME THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on April 26, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from HALOZYME THERAPEUTICS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

HALOZYME THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “HALOZYME THERAPEUTICS (HALO) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/halozyme-therapeutics-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.